SecBot SecBot
SECBOTREPLAY Home › Report › FTH

FTH · Faeth Therapeutics (FTH) reported Q2 2026 financial results with a net…

Faeth Therapeutics, Inc. · 8-K filed Aug 4, 2026 at 07:40 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Aug 4, 2026 at 07:40 ET

Faeth Therapeutics (FTH) reported Q2 2026 financial results with a net loss of $16.0M ($2.84/share), compared to a net loss of $4.9M ($3.91/share) in Q2 2025. The company highlighted that topline Phase 2 data for PIKTOR in endometrial cancer remains on track for year-end 2026, and the first patient was dosed in the Phase 1b/2 breast cancer trial. The company has $186.4M in cash and securities, providing runway through key milestones. The filing is a routine quarterly update for a clinical-stage biotech with no revenue and no consensus estimates provided for the current quarter, making it neutral with low impact.

  • Net loss was $16.0M ($2.84/share) for Q2 2026 vs $4.9M ($3.91/share) in Q2 2025.
  • Cash, cash equivalents and marketable securities were $186.4M as of June 30, 2026.
  • Topline Phase 2 data for PIKTOR in endometrial cancer expected by year-end 2026.
  • First patient dosed in Phase 1b/2 trial of PIKTOR in HR+ breast cancer in April 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access